Leukemia & lymphoma/Leukemia and lymphoma · 2009 · 27 citations · 9 references
Life SciencesCancer BiologyPharmacologyApoptosisCancer PharmacologyMolecular OncologyApoptosis In CancerApoptosis ModulationApoptosis PharmacologyApoptosis RegulationApoptotic SignalingBcl-2 Family ProteinsAnti-apoptotic ModulationB Cell ApoptosisBcl-2 Protein ExpressionBcl-2 Protein RegulationMtor SignalingPro-apoptotic Bax ActivationPro-apoptotic Bcl-2 ProteinsPro-apoptotic Effectors
B chronic lymphocytic leukemia (B-CLL) cells exist in patients as slowly accumulating resting as well as proliferating B cells. In this study, we examined whether Rapamycin and Curcumin, two naturally occurring compounds shown to have apoptotic effects, could selectively induce apoptosis in resting B-CLL cells. Mononuclear cells isolated from patients with B-CLL were treated with these agents and analysed by AnnexinV/propidium iodide binding, caspase activity, and changes in bcl-2/Bax ratio. Rapamycin and curcumin significantly induced apoptosis in resting B-CLL cells obtained from patients with CLL. Furthermore, rapamycin and curcumin increased caspase 9, 3 and 7 activity, decreased anti-apoptotic bcl-2 levels, and increased the pro-apoptotic protein Bax. These data suggest rapamycin and curcumin may be an effective treatment for B-CLL and are of high clinical significance considering the growing population of patients and lack of efficient treatment for this malignant disease.
9